Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy

European Journal of Pharmacology

Volumn 761, Issue , 2015, Pages 168-173

  Calzetta, Luigino ^a   Matera, Maria Gabriella ^b   Cazzola, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Airways smooth muscle; Clinical trials; COPD; Drug interaction; Dual bronchodilation; LABA; LAMA; Translation research

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL FUMARATE; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

AIRWAY; ARTICLE; BRONCHODILATATION; CHOLINERGIC TRANSMISSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; HUMAN; MATHEMATICAL MODEL; MUSCLE RELAXATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SMOOTH MUSCLE; ANIMAL; BRONCHOCONSTRICTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG INTERACTION; LUNG; METABOLISM; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84930615525     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.05.020     Document Type: Article

References (40)

1. R. Aalbers, M.R. Maleki-Yazdi, A. Hamilton, S. Waitere-Wijker, A. Pivovarova, O. Schmidt, and L. Bjermer Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD Eur. Respir. J. 40 2012 525 526s
2. E.D. Bateman, G.T. Ferguson, N. Barnes, N. Gallagher, Y. Green, M. Henley, and D. Banerji Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eur. Respir. J. 42 2013 1484 1494
3. C.K. Billington, and R.B. Penn Signaling and regulation of G protein-coupled receptors in airway smooth muscle Respir. Res. 4 2003 2
4. R. Buhl, F. Maltais, R. Abrahams, L. Bjermer, E. Derom, G. Ferguson, M. Flezar, J. Hebert, L. McGarvey, E. Pizzichini, J. Reid, A. Veale, L. Gronke, A. Hamilton, L. Korducki, K. Tetzlaff, S. Waitere-Wijker, H. Watz, and E. Bateman Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) Eur. Respir. J. 2015
5. L. Calzetta, C.P. Page, D. Spina, M. Cazzola, P. Rogliani, F. Facciolo, and M.G. Matera Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone J. Pharmacol. Exp. Ther. 346 2013 414 423
6. L. Calzetta, D. Spina, M. Cazzola, C.P. Page, F. Facciolo, E.A. Rendina, and M.G. Matera Pharmacological characterization of adenosine receptors on isolated human bronchi Am. J. Respir. Cell Mol. Biol. 45 2011 1222 1231
7. M. Cazzola, L. Calzetta, C.P. Page, B. Rinaldi, A. Capuano, and M.G. Matera Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi Am. J. Respir. Cell Mol. Biol. 45 2011 704 710
8. M. Cazzola, L. Calzetta, C.P. Page, P. Rogliani, F. Facciolo, A. Gavalda, and M.G. Matera Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi Eur. J. Pharmacol. 745 2014 135 143
9. M. Cazzola, L. Calzetta, P. Rogliani, D. Lauro, L. Novelli, C.P. Page, V. Kanabar, and M.G. Matera High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway Am. J. Respir. Cell Mol. Biol. 47 2012 509 516
10. M. Cazzola, L. Calzetta, A. Segreti, F. Facciolo, P. Rogliani, and M.G. Matera Translational Study Searching for Synergy between Glycopyrronium and Indacaterol Chronic Obstr. Pulm. Dis. 12 2015 175 181
11. M. Cazzola, and M.G. Matera Novel long-acting bronchodilators for COPD and asthma Br. J. Pharmacol. 155 2008 291 299
12. M. Cazzola, and M.G. Matera Bronchodilators: current and future Clin. Chest Med. 35 2014 191 201
13. M. Cazzola, and M. Molimard The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD Pulm. Pharmacol. Ther. 23 2010 257 267
14. M. Cazzola, A. Segreti, and M.G. Matera New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol Drug Des. Dev. Ther. 7 2013 1201 1208
15. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
16. Chou, T.C., Martin, N., 2005. CompuSyn for Drug Combinations: PC Software and User's Guide: a Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Values. ComboSyn, Paramus, NJ.
17. A. Gavalda, M. Miralpeix, I. Ramos, R. Otal, C. Carreno, M. Vinals, T. Domenech, C. Carcasona, B. Reyes, D. Vilella, J. Gras, J. Cortijo, E. Morcillo, J. Llenas, H. Ryder, and J. Beleta Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile J. Pharmacol. Exp. Ther. 331 2009 740 751
18. GOLD, 2014. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2014. (http://www.goldcopd.org/) (accessed April 2015).
19. M. Goldoni, and C. Johansson A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss Independence criterion and the Loewe additivity model Toxicol. In Vitro 21 2007 759 769
20. M. Gu, K. Wiesner, E. Rieper, and V. Vedral Quantum mechanics can reduce the complexity of classical models Nat. Commun. 3 2012 762
21. H.A. Kerstjens, M. Engel, R. Dahl, P. Paggiaro, E. Beck, M. Vandewalker, R. Sigmund, W. Seibold, P. Moroni-Zentgraf, and E.D. Bateman Tiotropium in asthma poorly controlled with standard combination therapy N. Engl. J. Med. 367 2012 1198 1207
22. K.M. Kew, S. Dias, and C.J. Cates Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Cochrane Database Syst. Rev. 2014 3
23. M.G. Matera, L. Calzetta, V. Parascandolo, G. Curradi, P. Rogliani, and M. Cazzola Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi Pulm. Pharmacol. Ther. 22 2009 478 482
24. M.G. Matera, L. Calzetta, D. Passeri, F. Facciolo, E.A. Rendina, C. Page, M. Cazzola, and A. Orlandi Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi Br. J. Pharmacol. 163 2011 1740 1754
25. M.G. Matera, L. Calzetta, A. Peli, A. Scagliarini, C. Matera, and M. Cazzola Immune sensitization of equine bronchus: glutathione, IL-1beta expression and tissue responsiveness Respir. Res. 6 2005 104
26. M.G. Matera, L. Calzetta, P. Rogliani, F. Bardaro, C.P. Page, and M. Cazzola Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi Pulm. Pharmacol. Ther. 24 2011 221 226
27. M.G. Matera, L. Calzetta, A. Sanduzzi, C.P. Page, and M. Cazzola Effects of neuraminidase on equine isolated bronchi Pulm. Pharmacol. Ther. 21 2008 624 629
28. M.G. Matera, L. Calzetta, A. Segreti, and M. Cazzola Emerging drugs for chronic obstructive pulmonary disease Expert Opin. Emerg. Drugs 17 2012 61 82
29. M.G. Matera, P. Rogliani, B. Rinaldi, and M. Cazzola Umeclidinium bromide+vilanterol for the treatment of chronic obstructive pulmonary disease Expert Rev. Clin. Pharmacol. 8 2015 35 41
30. H. Meurs, B.G. Dekkers, H. Maarsingh, A.J. Halayko, J. Zaagsma, and R. Gosens Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target Pulm. Pharmacol. Ther. 26 2013 145 155
31. J. Nichols Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease Pharmacotherapy 27 2007 447 454
32. G. Pelaia, R. Maselli, and M.G. Matera Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium Pharmacology 94 2014 249 258
33. G.J. Rodrigo, and V. Plaza Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review Chest 146 2014 309 317
34. P. Rogliani, L. Calzetta, E.A. Rendina, D. Massullo, M. Dauri, B. Rinaldi, A. Capuano, and M.G. Matera The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle Pulm. Pharmacol. Ther. 26 2013 325 331
35. P. ͆liwiński, D.W. Perng, A. Chuchalin, and P.W. Jones P137 Efficacy and safety of once-daily aclidinium bromide 200 μg in combination with formoterol in patients with COPD Thorax 65 2010 A136-A136
36. D.A. Sykes, M.R. Dowling, J. Leighton-Davies, T.C. Kent, L. Fawcett, E. Renard, A. Trifilieff, and S.J. Charlton The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther. 343 2012 520 528
37. R.J. Tallarida Revisiting the isobole and related quantitative methods for assessing drug synergism J. Pharmacol. Exp. Ther. 342 2012 2 8
38. D.P. Tashkin, and G.T. Ferguson Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease Respir. Res. 14 2013 49
39. T. van der Molen, and M. Cazzola Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes Prim. Care Respir. J. 21 2012 101 108
40. J.A. Wedzicha, M. Decramer, J.H. Ficker, D.E. Niewoehner, T. Sandstrom, A.F. Taylor, P. D'Andrea, C. Arrasate, H. Chen, and D. Banerji Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study Lancet Respir. Med. 1 2013 199 209